Search
VIR201
go.drugbank.com/drugs/DB05110Experimentalis an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Sobuzoxane
go.drugbank.com/drugs/DB21119ExperimentalSobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative. … Sobuzoxane has a monoisotopic molecular weight of 514.23 Da.
Categories: Topoisomerase II Inhibitors, Heterocyclic Compounds, 1-RingRauwolfia serpentina root
go.drugbank.com/drugs/DB09363InvestigationalRauwolfia (Rauwolfia serpentina), also spelled _ravolphia_, is a medicinal plant in the milkweed family. The root of the plant is ground into a powder or sold in tablets or capsules. … It is a compound commonly used in Asian medicine, which includes traditional Ayurvedic medicine native to India.
Categories: Heterocyclic Compounds, 2-RingCX501
go.drugbank.com/drugs/DB05174InvestigationalIt is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Chromanol
go.drugbank.com/drugs/DB13111InvestigationalChromanol has been used in trials studying the treatment of Prostate Cancer.
Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-RingDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSynonyms: (S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamideOtelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
GnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". … The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation
DDP733
go.drugbank.com/drugs/DB05049InvestigationalIt is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).
Categories: Heterocyclic Compounds, 1-Ring